Class
Undo See the current
NY batch Contact Us for an
Early Intro
Dahlia Biosciences
RNA analysis tools for research and diagnostic applications
The flow cytometry research market is estimated to be >$1.9 billion in 2020 growing 7%, of which approximately $1.3B is driven by annual reagents expenditures.

Dahlia Biosciences is providing the next generation of multiplexed in situ single-cell RNA analysis tools for research and diagnostic applications. Our vision is to empower scientists to study and isolate cells at high resolution via sensitive, robust, and multiplexed RNA detection in both fixed and live cells.

Un Kwon, CEO
"Flow cytometry is a powerful technology to study complex cell populations, and is ubiquitous in the development of immuno-oncology and cell based therapies. We see a significant opportunity to scale single-cell RNA analysis to millions of cells by combining the throughput of flow cytometry with our CRISPR-based RNA detection reagents."
Dahlia Biosciences
Un Kwon, CEO
"Flow cytometry is a powerful technology to study complex cell populations, and is ubiquitous in the development of immuno-oncology and cell based therapies. We see a significant opportunity to scale single-cell RNA analysis to millions of cells by combining the throughput of flow cytometry with our CRISPR-based RNA detection reagents."
Sun Genomics
Microbiome health company curing dysbiosis through precision probiotics
Recent scientific research indicated that between 30 and 50% of all people with autism suffer from chronic gastrointestinal (GI) problems.

Sun Genomics is a microbiome health company focused on curing dysbiosis through personalized probiotics. Our platform enables the highest resolution profiling of customer gut makeup, empowering them to make and track changes over time.

Sunny Jain, CEO
Our vast database of over 100,000 genomes allows our team of microbiome scientists to make calls related to not only bacterial strains but fungi, parasites, and viruses found in the gut microbiome, thereby allowing us to create custom probiotics for the end user.
Sun Genomics
Sunny Jain, CEO
Our vast database of over 100,000 genomes allows our team of microbiome scientists to make calls related to not only bacterial strains but fungi, parasites, and viruses found in the gut microbiome, thereby allowing us to create custom probiotics for the end user.
Prime Roots
Fungi for foodies
A proud moment for Prime Roots is when they discovered Lizzo was praising this product on her Instagram stories

Prime Roots (formerly Terramino Foods) is revolutionizing protein. We are using fungi super protein as the base of our delicious high-protein products that are good for you and the world.

Kimberlie Le, CEO
We believe that putting our community first gives us unique insight, as well as the ability for consumers to have dialogue with us so that we are ensuring that we are making the best products that our community of eaters crave.
Prime Roots
Kimberlie Le, CEO
We believe that putting our community first gives us unique insight, as well as the ability for consumers to have dialogue with us so that we are ensuring that we are making the best products that our community of eaters crave.
NURO CORP
One of the world's leading manufacturers of non-invasive Neurotechnology
1 in 4 adults in the World will be a victim of Stroke and 20% of them will reach a state of Akinetic Mutism, fully aware yet entrapped by their body, unable to communicate.

NURO is the architect of NUOS, KOMPOS, PAD and MENTIS, all leading non-invasive neurotechnologies for healthcare and non-healthcare applications. NURO’s implementations have reached 8 countries on 4 continents.

Francois Gand, CEO
Our team delivers life-changing non-invasive neurological solutions with groundbreaking technology and without any of the risks from surgery and foreign body insertion into the human brain.
NURO CORP
Francois Gand, CEO
Our team delivers life-changing non-invasive neurological solutions with groundbreaking technology and without any of the risks from surgery and foreign body insertion into the human brain.
Neurocarrus Inc
Developing long acting non-opioid chronic pain medications
More than 11 million people abused prescription opioids in 2016, and the CDC estimates it has an economic cost of $80B a year

Neurocarrus is a biotechnology company developing a novel drug delivery technology to safely disrupt pain signals without addiction-forming medications or disruption of muscular control.

Benjamin Pavlik, PhD, CEO
Our success as a company would change the healthcare industry by providing an alternative to opioids as a front-line pain management solution.
Neurocarrus Inc
Benjamin Pavlik, PhD, CEO
Our success as a company would change the healthcare industry by providing an alternative to opioids as a front-line pain management solution.
GateHouse Bio (fka sRNAlytics)
An RNA therapeutic company
It takes over 4 years and dozens of tests to even diagnose it, and even those are wrong... One in four patients in dementia clinical trials don't even have early-stage dementia, and leads to the 99% drug failure rate.

Gatehouse Bio is a biotech company developing RNA therapeutics using AI that harnesses the power of small RNA. Their platform discovers disease-associated mutations and designs therapeutics to counteract their effect.

David Salzman, PhD, CEO
"I left my job at Biogen to pursue a vision to turn small RNAs into the next generation biomarkers."
GateHouse Bio (fka sRNAlytics)
David Salzman, PhD, CEO
"I left my job at Biogen to pursue a vision to turn small RNAs into the next generation biomarkers."
Lingrove
Creating ‘wood’ without the tree
87% of old timber forests are gone forever. They're never coming back.

Creating ‘wood’ without the tree. Their formable, natural fiber and resin replicates the performance, look, feel and re-usability of premium wood from scalable, carbon negative materials.

Joe Luttwak, CEO
We’re pursuing big customers and large material flows to really make an impact.
Lingrove
Joe Luttwak, CEO
We’re pursuing big customers and large material flows to really make an impact.
Jointechlabs, Inc.
Pioneering access to high-quality fat grafts, fat-derived stem cells, and cell therapies
Global regenerative medicine market will reach $50B by 2025

Jointechlabs Inc. is an emerging leader in point-of-care regenerative and rejuvenation medicine therapies. We have patented, portable medicine products that enable personalized therapies. Our medical device allows doctors, clinics, and hospitals to provide safe- and cost-effective non-surgical regenerative and healing treatments for patients.

Nishit Pancholi, MD, COO
The use of autologous body fats makes the procedure safer and better, and ours is the only solution that can process the fat at point of care at half the price.
Jointechlabs, Inc.
Nishit Pancholi, MD, COO
The use of autologous body fats makes the procedure safer and better, and ours is the only solution that can process the fat at point of care at half the price.
Beeflow
Increasing crop yields by providing the next generation of bee pollination to farmers
The number of bee colonies per hectare has declined by 90 percent since 1962... making pollination harder than ever

Beeflow develops smart and strong bees for crop pollination. With our technologies, farmers can increase crop yields up to 90%, target specific crops for pollination, and substantially reduce bee population decline.

Matias Viel, CEO
"No one has paid much attention to pollination, and we are trying to demonstrate to farmers that pollination can be a solution to achieve the demand for food that the world will have in the next few years."
Beeflow
Matias Viel, CEO
"No one has paid much attention to pollination, and we are trying to demonstrate to farmers that pollination can be a solution to achieve the demand for food that the world will have in the next few years."